Merck KGaA generics biz draws suitors

Share this article:
At least five bidders are vying for the generics operation of German pharma firm Merck KGaA, The Wall Street Journal reports. The bids, from other generics firms as well as from private equity, range from $5-$6.5 billion, the newspaper said. Generic drug firms entering bids by this week’s Monday deadline were Teva Pharmaceutical, Mylan Labs, Actavis Group and Ranbaxy Labs. Private-equity firms Bain Capital and Apax Partners made a joint offer, according to the WSJ report. And Indian generics maker Cipla is advising a second offer from a consortium consisting mostly of private-equity companies. Merck KGaA started exploring options for the generics unit, which had 2006 sales of $2.4 billion, last month. Final bids are due by the end of April, a source told the newspaper, with Merck due to compile a short list of suitors by next week. Bear Stearns is handling talks with potential buyers. A successful bid by Ranbaxy would make it the third-biggest biggest generics firm, behind Teva and Novartis’ Sandoz unit.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...